INTS: Intensity Therapeutics Inc. Stocks News on November 25, 2025

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

INTS

PR Newswire

19 days ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

INTS

MT Newswires

25 days ago

Intensity Therapeutics Prices $4 Million Direct Offering

INTS

Associated Press Finance

25 days ago

BC-Most Active Stocks

Intensity Therapeutics stock up nearly 400% on solid tumour data

INTS

Clinical Trials Arena

25 days ago

Intensity Therapeutics stock up nearly 400% on solid tumour data

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

INTS

PR Newswire

25 days ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

INTS

PR Newswire

a month ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

INTS

PR Newswire

5 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

INTS

PR Newswire

5 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

INTS

MT Newswires

5 months ago

Intensity Therapeutics Plans Public Share Offering to Fund Cancer Trial

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

INTS

PR Newswire

5 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

INTS

PR Newswire

5 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

INTS

PR Newswire

6 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

INTS

PR Newswire

6 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

INTS

MT Newswires

6 months ago

Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

INTS

PR Newswire

6 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

INTS

PR Newswire

7 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

INTS

PR Newswire

7 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

INTS

Zacks

7 months ago

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

INTS

Zacks

8 months ago

Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

INTS

PR Newswire

8 months ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

INTS

PR Newswire

10 months ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

INTS

PR Newswire

10 months ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

INTS

MT Newswires

a year ago

Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares

Intensity Therapeutics reports positive results of INT230-6 in breast cancer

INTS

TipRanks

a year ago

Intensity Therapeutics reports positive results of INT230-6 in breast cancer

INTS

MT Newswires

a year ago

Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

INTS

PR Newswire

a year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

INTS

PR Newswire

a year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

INTS

PR Newswire

a year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

INTS

PR Newswire

a year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

3 US Penny Stocks With Market Caps Under $200M To Watch

INTS

Simply Wall St.

a year ago

3 US Penny Stocks With Market Caps Under $200M To Watch

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

INTS

PR Newswire

a year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

INTS

PR Newswire

a year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

INTS

PR Newswire

a year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

INTS

PR Newswire

a year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

INTS

PR Newswire

a year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

INTS

Simply Wall St.

a year ago

Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

INTS

PR Newswire

2 years ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

INTS

MT Newswires

2 years ago

Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

INTS

PR Newswire

2 years ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

INTS

PR Newswire

2 years ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

INTS

PR Newswire

2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

INTS

GlobeNewswire

2 years ago

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

INTS

PR Newswire

2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

INTS

PR Newswire

2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

INTS

PR Newswire

2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

The L.S. Starrett Company (NYSE:SCX) surges 11%; individual investors who own 44% shares profited along with institutions

INTS

Simply Wall St.

2 years ago

The L.S. Starrett Company (NYSE:SCX) surges 11%; individual investors who own 44% shares profited along with institutions

INTS

GlobeNewswire

2 years ago

Sportsman’s Warehouse Holdings, Inc. Appoints Steven R. Becker to its Board of Directors

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

INTS

StockStory

2 years ago

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

Bright Health Group, Inc.'s (NYSE:BHG) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week

INTS

Simply Wall St.

2 years ago

Bright Health Group, Inc.'s (NYSE:BHG) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last week

Nutex Health Announces Pricing of $10.0 Million Registered Direct Offering of Common Stock and Warrants

INTS

PR Newswire

2 years ago

Nutex Health Announces Pricing of $10.0 Million Registered Direct Offering of Common Stock and Warrants

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

INTS

Simply Wall St.

2 years ago

Nutex Health Inc.'s (NASDAQ:NUTX) top owners are retail investors with 47% stake, while 43% is held by insiders

Here's Why California BanCorp (NASDAQ:CALB) Has Caught The Eye Of Investors

INTS

Simply Wall St.

2 years ago

Here's Why California BanCorp (NASDAQ:CALB) Has Caught The Eye Of Investors

Garmin (GRMN) Boosts Smartwatch Offerings With Lily 2 Series

INTS

Zacks

2 years ago

Garmin (GRMN) Boosts Smartwatch Offerings With Lily 2 Series

Why Investors Need to Take Advantage of These 2 Auto-Tires-Trucks Stocks Now

INTS

Zacks

2 years ago

Why Investors Need to Take Advantage of These 2 Auto-Tires-Trucks Stocks Now

ASP Isotopes Inc. Provides Corporate Update

INTS

GlobeNewswire

2 years ago

ASP Isotopes Inc. Provides Corporate Update

INTS

Zacks

2 years ago

Zacks Industry Outlook Highlights Advanced Micro Devices, ASE Technology, Cirrus Logic and QuickLogic

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

INTS

GlobeNewswire

2 years ago

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

INTS

Business Wire

2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

INTS

PR Newswire

2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

INTS

Simply Wall St.

2 years ago

Intensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth Plans

Are Investors Undervaluing Frontdoor, Inc. (NASDAQ:FTDR) By 47%?

INTS

Simply Wall St.

2 years ago

Are Investors Undervaluing Frontdoor, Inc. (NASDAQ:FTDR) By 47%?

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

INTS

Zacks

2 years ago

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

Electrovaya Announces Potential Delay In Filing Year-End Reporting Documents

INTS

CNW Group

2 years ago

Electrovaya Announces Potential Delay In Filing Year-End Reporting Documents

Don't Race Out To Buy First Guaranty Bancshares, Inc. (NASDAQ:FGBI) Just Because It's Going Ex-Dividend

INTS

Simply Wall St.

2 years ago

Don't Race Out To Buy First Guaranty Bancshares, Inc. (NASDAQ:FGBI) Just Because It's Going Ex-Dividend

Turtle Beach Unveils Its Groundbreaking VelocityOne Flightdeck – the Ultimate Universal HOTAS Flight Simulation Control System

INTS

Business Wire

2 years ago

Turtle Beach Unveils Its Groundbreaking VelocityOne Flightdeck – the Ultimate Universal HOTAS Flight Simulation Control System

INTS

PR Newswire

2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

INTS

PR Newswire

2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Rigetti Launches the Novera QPU, the Company’s First Commercially Available QPU

INTS

GlobeNewswire

2 years ago

Rigetti Launches the Novera QPU, the Company’s First Commercially Available QPU

New Trinseo PMMA Depolymerization Plant Reimagines Plastics Value Chain With Sustainability In Mind

INTS

Business Wire

2 years ago

New Trinseo PMMA Depolymerization Plant Reimagines Plastics Value Chain With Sustainability In Mind

INTS

Business Wire

2 years ago

Western Asset Mortgage Capital Corporation Announces Stockholder Approval of Merger With AG Mortgage Investment Trust

DoubleLine Opportunistic Credit Fund Declares December 2023 Distribution

INTS

PR Newswire

2 years ago

DoubleLine Opportunistic Credit Fund Declares December 2023 Distribution

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

INTS

PR Newswire

2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Shareholders in SuRo Capital (NASDAQ:SSSS) are in the red if they invested three years ago

INTS

Simply Wall St.

2 years ago

Shareholders in SuRo Capital (NASDAQ:SSSS) are in the red if they invested three years ago

INTS

GlobeNewswire

2 years ago

First Capital, Inc. Announces Quarterly Dividend

Should You Be Adding First Capital (NASDAQ:FCAP) To Your Watchlist Today?

INTS

Simply Wall St.

2 years ago

Should You Be Adding First Capital (NASDAQ:FCAP) To Your Watchlist Today?

AG Mortgage Investment Trust, Inc. Announces Second Interim Fourth Quarter Common Dividend of $0.05 Per Share

INTS

Business Wire

2 years ago

AG Mortgage Investment Trust, Inc. Announces Second Interim Fourth Quarter Common Dividend of $0.05 Per Share

COO & CFO of Gossamer Bio Picks Up 76% More Stock

INTS

Simply Wall St.

2 years ago

COO & CFO of Gossamer Bio Picks Up 76% More Stock

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

INTS

PR Newswire

2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Heritage Global Inc. (NASDAQ:HGBL) Q3 2023 Earnings Call Transcript

INTS

Insider Monkey

2 years ago

Heritage Global Inc. (NASDAQ:HGBL) Q3 2023 Earnings Call Transcript

Heritage Global Inc. Just Missed Earnings - But Analysts Have Updated Their Models

INTS

Simply Wall St.

2 years ago

Heritage Global Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

INTS

GlobeNewswire

2 years ago

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

INTS

Business Wire

2 years ago

Olo to Present at Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences

INTS

GlobeNewswire

2 years ago

IO Biotech Announces Participation in Upcoming Investor Conferences

AG Mortgage Investment Trust, Inc. (NYSE:MITT) Q3 2023 Earnings Call Transcript

INTS

Insider Monkey

2 years ago

AG Mortgage Investment Trust, Inc. (NYSE:MITT) Q3 2023 Earnings Call Transcript

INTS

Thomson Reuters StreetEvents

2 years ago

Q3 2023 SoundThinking Inc Earnings Call

INTS

Motley Fool

2 years ago

Here's Why Olo Stock Got Creamed Today

Best Momentum Stock to Buy for November 7th

INTS

Zacks

2 years ago

Latest Intensity Therapeutics Inc. (INTS) News on November 25, 2025

Share on Social Networks: